Women's Health

FDA Approval Introduces a First-in-Class Neurokinin Receptor Agonist Shown to Reduce Vasomotor Symptom Frequency and Improve Sleep Quality in Postmenopausal Women

How can a natural biological evolution with so many consequences get relatively little attention from research and practice?

Hypertensive disorders of pregnancy confer increased cardiovascular risk, with heightened risk corresponding to more severe hypertension.

The FDA lifts the black box warning on hormone replacement therapy, empowering women with new options for managing menopause symptoms.

Maternal COVID-19 infection raises concerns about neurodevelopmental disorders in children, emphasizing the need for effective fever and infection management during pregnancy.

Research highlights significant barriers to contraceptive use and reproductive health management for women with chronic kidney disease (CKD), urging improved nephrology care.

Research highlights the link between earlier menopause, cardiac function, and brain health, emphasizing the need for sex-specific dementia risk strategies.

Research highlights the impact of provider type on menopause treatment, revealing a need for standardized education to improve care quality for women.

Elinzanetant, the first FDA-approved nonhormonal treatment for menopause-related vasomotor symptoms, offers women a new, effective relief option.

The authors wrote that their findings show a necessary update following early data from the Women’s Health Initiative.

Further research is needed to better understand which characteristics may better predict who are more likely to benefit from estrogen-based menopausal hormonal therapy (MHT) for anxiety.

New clinical trial results suggest G-CSF as a promising alternative for managing hot flashes in menopausal women, without the risks of traditional therapies.

Research highlights the impact of sleep disturbances and vasomotor symptoms (VMS) on HRQoL in women transitioning to menopausal period, emphasizing the need for effective management.

When treating vasomotor symptoms (VMS), 15- and 20-mg doses of estetrol (E4) did not significantly hinder postmenopausal women’s blood pressure, including those with cardiovascular risks.

New research reveals how menopausal hormone therapy impacts cognitive health in postmenopausal women, highlighting the importance of administration routes and estrogen types.

Elinzanetant was effective in women with low vasomotor symptom (VMS) burden and those with endocrine therapy-caused VMS.

The phase 3 trial demonstrated significant improvements in overall and progression-free survival, reinforcing the combination as a standard-of-care option across MMR subgroups.

Nicoletta Colombo, MD, PhD, discusses why metronomic chemotherapy dosing and careful regimen design may have driven the success of the KEYNOTE-B96 trial.

Flu vaccination during pregnancy safeguards maternal and infant health, reducing severe illness risks and providing essential immunity to newborns.

Research reveals the impact of SSRIs on pregnancy, highlighting risks and benefits for maternal mental health and fetal development.

In a Swedish cohort, young women with symptomatic long COVID were found to be at higher risk of postural orthostatic tachycardia syndrome (POTS), conferring additional burden.

Discover how supplements support women's health during menopause, enhancing well-being and easing symptoms effectively.

The FDA linked cerebral folate deficiency to developmental delays with autistic features, although research remains ongoing.

However, experts say that a causal relationship between acetaminophen and autism has not been established.

HHS and Robert F. Kennedy Jr prepare to unveil a report linking Tylenol use in pregnancy to autism, despite inconsistent study findings.